全文获取类型
收费全文 | 142篇 |
免费 | 6篇 |
国内免费 | 22篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 3篇 |
基础医学 | 24篇 |
口腔科学 | 4篇 |
临床医学 | 25篇 |
内科学 | 18篇 |
皮肤病学 | 11篇 |
神经病学 | 2篇 |
特种医学 | 6篇 |
外科学 | 5篇 |
综合类 | 25篇 |
预防医学 | 8篇 |
眼科学 | 2篇 |
药学 | 26篇 |
中国医学 | 1篇 |
肿瘤学 | 9篇 |
出版年
2023年 | 2篇 |
2021年 | 3篇 |
2020年 | 2篇 |
2019年 | 3篇 |
2018年 | 2篇 |
2016年 | 1篇 |
2015年 | 6篇 |
2014年 | 6篇 |
2013年 | 2篇 |
2012年 | 1篇 |
2011年 | 1篇 |
2010年 | 8篇 |
2009年 | 13篇 |
2008年 | 8篇 |
2007年 | 19篇 |
2006年 | 6篇 |
2005年 | 10篇 |
2004年 | 4篇 |
2003年 | 5篇 |
2002年 | 5篇 |
2001年 | 3篇 |
2000年 | 1篇 |
1999年 | 2篇 |
1998年 | 10篇 |
1997年 | 16篇 |
1996年 | 5篇 |
1995年 | 4篇 |
1994年 | 2篇 |
1993年 | 2篇 |
1991年 | 3篇 |
1990年 | 6篇 |
1989年 | 1篇 |
1987年 | 2篇 |
1980年 | 1篇 |
1979年 | 1篇 |
1977年 | 3篇 |
1976年 | 1篇 |
排序方式: 共有170条查询结果,搜索用时 0 毫秒
11.
12.
13.
REM sleep behaviour disorder (RSBD) is a recently described parasomnia characterised by a history of excessive nocturnal motor activity and absence of muscle atonia during REM sleep. Only limited literature is available on this condition. The exact prevalence is unclear, but recent studies suggest it might not be an uncommon condition. The elderly are more often affected and there is a male preponderance. While transient RSBD can be seen after taking certain drugs or during drug withdrawal, the chronic type is usually idiopathic or associated with an underlying degenerative neurological condition. It can result in considerable distress and/or serious injury to the patients or their bed partners. Differential diagnoses include sleep-walking, night terrors, nightmares, nocturnal seizures, obstructive sleep apnoea, post-traumatic stress disorder, dissociative states and nocturnal confusional states. The dramatic response to clonazepam highlights the importance of recognition and appropriate treatment of this sleep disorder. 相似文献
14.
目的:蒿甲醚除了具有良好的临床治疗作用外,对正常组织有极大的副作用。实验拟观察蒿甲醚对大鼠肺泡Ⅱ型上皮细胞的影响。方法:实验于2005-09-20/2007-03-10在山东省泰山医学院生命科学研究所、中心实验室和机能实验室完成。①实验材料:蒿甲醚购自昆明制药厂,分析纯,使用前先进行预处理,处理方法:研磨后用溶液配成1g/L的母液,超声助溶解后供实验用。Wistar大鼠70只,体质量(70±15)g,雌雄不拘,由山东大学医学院实验动物中心提供。实验过程中对动物处置符合动物伦理学标准。②实验方法:将大鼠随机分为普通饲料对照组(n=10)和实验组(n=60),实验组分6个亚组,分别在饲料中加入0.1,0.2,0.4,0.8,1.6,3.2mg/kg的蒿甲醚。采用单细胞凝胶电泳技术观察大鼠肺泡Ⅱ型上皮细胞DNA的改变。结果:70只大鼠,饲养过程中实验组死亡6只,死亡原因为饲料添加蒿甲醚造成。当饲料中的蒿甲醚浓度为0.1mg/kg时,大鼠肺泡Ⅱ型上皮细胞DNA损伤率与对照组相比,差异无统计学意义;饲料中的蒿甲醚浓度超过0.2mg/kg时,大鼠肺泡Ⅱ型上皮细胞DNA损伤率明显增加,与对照组相比,差异有统计学意义。且损伤程度与饲料中蒿甲醚含量呈正相关。结论:当饲料中的蒿甲醚浓度超过0.2mg/kg时,蒿甲醚可在一定程度上改变肺泡Ⅱ型上皮细胞的DNA生物学特性。且随着蒿甲醚浓度的升高,这种损害更为明显。 相似文献
15.
Wierzbicki AS; Lumb PJ; Semra YK; Crook MA 《QJM : monthly journal of the Association of Physicians》1998,91(4):291-294
Lipid targets can be difficult to attain in familial hypercholesterolaemia.
To compare atorvastatin with simvastatin- fenofibrate and
simvastatin-cholestyramine therapy, we studied 54 patients with familial
hypercholesterolaemia over periods of 2-6 months on each therapeutic
regimen. The atorvastatin regimen reduced total cholesterol by 41.2 +/-
11.2%, LDL by 45.6 +/- 15.5%, triglycerides by 33.8 +/- 24.8%, and
increased HDL by 2.3 +/- 37.0%. Simvastatin- fenofibrate therapy achieved
reductions of 33.9 +/- 8.5% in cholesterol, 42.0 +/- 12.2% in LDL, 34.7 +/-
38.3% for triglycerides, and a 25.4 +/- 55.1% increase in HDL.
Simvastatin-cholestyramine gave a reduction of 31.3 +/- 11.8% in
cholesterol, 36.0 +/- 14.4% in LDL, 13.7 +/- 36.3% in triglycerides, and a
1.1 +/- 30.3% rise in HDL. The atorvastatin regimen was marginally but not
significantly better than simvastatin-fenofibrate in improving the LDL:HDL
ratio, LDL:apoB and and apolipoprotein B:A1 ratios. Eleven patients (20.4%)
had side- effects: two discontinued atorvastatin due to side-effects; two
patients had rashes; six had myalgia and two had diarrhoea.
Gastrointestinal side-effects were described in 16 (30.1%) patients on
simvastatin-cholestyramine therapy and four cases of myalgia (11.2%) were
seen with simvastatin-fenofibrate. In nine patients on atorvastatin (20.4%)
a 30% or greater fall in HDL was observed, compared to five patients with
resin therapy (9.2%) and two with fibrate therapy (5.5%). There were no
significant differences in liver or muscle biochemistry between the
regimens, but atorvastatin did raise transaminase and creatine kinase
concentrations significantly compared to pre-treatment values (p = 0.001).
Atorvastatin significantly improves the lipid profile in most patients
compared with other regimens. It has a comparable incidence of side-effects
to combination therapy regimens.
相似文献
16.
目的:采用腹腔注射链脲佐菌素 切除双侧卵巢复合方法建立绝经后糖尿病骨质疏松大鼠模型,观察糖尿病骨质疏松大鼠破骨细胞的改变。方法:实验于2003-12/2004-08在河北医科大学第三医院中心实验室完成。①实验材料:选用2.5~3个月龄清洁级雌性Wistar大鼠60只。②实验分组:完全随机设计分为6组:正常对照组、正常假手术组及正常双侧卵巢切除组均为8只;糖尿病对照组、糖尿病假手术组及糖尿病双侧卵巢切除组均为12只。③实验干预:采用链脲佐菌素诱导制备糖尿病大鼠模型1周后,将大鼠麻醉结扎输卵管切除卵巢。假手术组大鼠不作卵巢切除,余操作同去卵巢组。卵巢切除后0,2,4,8周随机选择各组大鼠1只,收集骨髓,进行体外骨髓破骨细胞样细胞的培养。④实验评估:切除双侧卵巢后2,4,8周时测量各组大鼠体质量、血糖;细胞培养7d后,进行细胞固定和抗酒石酸酸性磷酸酶染色(抗酒石酸酸性磷酸酶染色阳性且细胞核≥3个的细胞认定为破骨细胞样细胞);倒置显微镜计数破骨细胞样细胞数量。结果:制成糖尿病模型及切除卵巢后,3组糖尿病大鼠死亡7只,进入结果分析53只。①各组大鼠血糖和体质量的变化:切除卵巢0,2,4,8周,3组糖尿病大鼠血糖均高于正常组(P<0.01),体质量均低于正常组(P<0.01);4周时,正常双侧卵巢切除组体质量高于同期正常对照组和正常假手术组;糖尿病双侧卵巢切除组体质量在2,4,8周时均高于同期糖尿病对照组和糖尿病假手术组(4周P<0.05,8周P<0.01)。②切除卵巢后各组大鼠体外培养的破骨细胞样细胞形成的变化:糖尿病双侧卵巢切除大鼠破骨细胞多于糖尿病大鼠及正常去卵巢大鼠,且破骨细胞数量随着去卵巢的时间和糖尿病病程延长而增加。③骨髓来源的体外破骨细胞样细胞的形成与血糖、糖尿病病程及去卵巢时间的相关性分析:破骨细胞数量与糖尿病病程呈正相关,而与血糖增高的程度无关(r=-0.537;P=0.109)。结论:①卵巢切除对大鼠的血糖无显著影响,对大鼠体质量的影响被糖尿病减弱,在糖尿病早期破骨细胞样细胞的形成已有增加。②破骨细胞形成增加可能是绝经后糖尿病骨质疏松的原因之一。 相似文献
17.
18.
19.
20.
BC SHARMA RP SINGH YK CHAWLA KL NARASIMHAN KLN RAO SK MITRA JB DILAWARI 《Journal of gastroenterology and hepatology》1997,12(8):582-584
Shunt surgery is considered to be the treatment of choice in patients with non-cirrhotic portal hypertension. There is little data on the effect of side-to-side lieno-renal (SSLR) shunt on oesophageal variceal size, splenic size and splenic pulp pressure (SPP) in patients with non-cirrhotic portal hypertension. We evaluated pre- and postoperatively endoscopic grading of varices, splenic size and SPP for predicting shunt patency in 86 patients with non-cirrhotic portal hypertension: 56 with extrahepatic portal venous obstruction (EHPVO) and 30 with non-cirrhotic portal fibrosis (NCPF). The EHPVO patients with patent shunts (n= 47) showed significant reduction in SPP (pre-operative 43.56±7.9 vs postoperative 29.96±7.7 cm of saline), splenic size (6.5±2.8 vs 4.00±2.6 cm below costal margin) and varices grades (2.96±0.5 vs 0.92±0.8). Patients with blocked shunt (n= 9) did not show significant reduction in SPP and varices grades. However, there was reduction in spleen size (8.6±3.0 vs 6.3±4.3). In the NCPF group, 28 had patent shunts and showed significant reduction in SPP (46.3±13.5 vs 33.8±7.6 cm of saline), splenic size (9.1±3.3 vs 6.8±4.6 cm below costal margin) and varices grades (2.8±0.7 vs 1.05±0.96). As only two patients with NCPF had blocked shunts, no statistical comparison between patients with patent and patients with blocked shunts could be done. In conclusion, following SSLR, there is a significant reduction in SPP and varices grades in patients with patent shunts. Endoscopic grading of varices can be used to predict shunt patency. However, spleen size is not a good criteria for predicting shunt patency. 相似文献